RetinalGenix Technologies (RTGN) Net Equity Issued and Repurchased (2020 - 2025)
RetinalGenix Technologies (RTGN) reported Net Equity Issued and Repurchased of $212000.0 for Q4 2025, up 116.23% on a YoY basis from $98045.0 in Q4 2024, and up 116.23% sequentially from $98045.0 in Q4 2024.
RetinalGenix Technologies (RTGN) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
RetinalGenix Technologies (RTGN) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $212000.0 in Q4 2025.
- For the quarter ending Q4 2025, Net Equity Issued and Repurchased rose 116.23% year-over-year to $212000.0; the trailing twelve-month figure through Dec 2025 stood at $715089.0 (up 42.14% YoY), and the FY2025 full-year result was $398000.0, down 20.89% from the prior year.
- Net Equity Issued and Repurchased advanced to $212000.0 in Q4 2025, from $98045.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $398097.0 in Q1 2021 to a low of $60500.0 in Q1 2022.
- A 4-year average of $206532.0 and a median of $212000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Across the five-year window, Net Equity Issued and Repurchased plunged 84.8% in 2022 and soared 116.23% in 2025, its largest moves.
- Tracing RTGN's Net Equity Issued and Repurchased over 4 years: stood at $258934.0 in 2021, then plunged by 76.63% to $60500.0 in 2022, then jumped by 62.06% to $98045.0 in 2024, then soared by 116.23% to $212000.0 in 2025.
- Business Quant data shows RTGN's Net Equity Issued and Repurchased at $212000.0 in Q4 2025, $98045.0 in Q4 2024, and $305044.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 97.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 12.70 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212,000.00 |
| Dec 31, 2025 | 212,000.00 |
| Dec 31, 2024 | 98,045.00 |
| Dec 31, 2024 | 98,045.00 |
| Sep 30, 2024 | 305,044.00 |
| Sep 30, 2024 | 305,044.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2022 | 60,500.00 |
| Mar 31, 2022 | 60,500.00 |
| Dec 31, 2021 | 258,934.00 |
| Dec 31, 2021 | 258,934.00 |
| Sep 30, 2021 | 162,792.00 |
| Sep 30, 2021 | 162,792.00 |
| Jun 30, 2021 | 263,376.00 |
| Jun 30, 2021 | 263,376.00 |
| Mar 31, 2021 | 398,097.00 |
| Mar 31, 2021 | 398,097.00 |
| Dec 31, 2020 | 343,810.00 |
| Dec 31, 2020 | 343,810.00 |